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Abstract
Background:  Mefloquine is a clinically important antimalaria drug, which is often not well
tolerated. We critically reviewed 516 published case reports of mefloquine adverse effects, to
clarify the phenomenology of the harms associated with mefloquine, and to make
recommendations for safer prescribing.
Presentation: We postulate that many of the adverse effects of mefloquine are a post-hepatic
syndrome caused by primary liver damage. In some users we believe that symptomatic thyroid
disturbance occurs, either independently or as a secondary consequence of the hepatocellular
injury. The mefloquine syndrome presents in a variety of ways including headache, gastrointestinal
disturbances, nervousness, fatigue, disorders of sleep, mood, memory and concentration, and
occasionally frank psychosis. Previous liver or thyroid disease, and concurrent insults to the liver
(such as from alcohol, dehydration, an oral contraceptive pill, recreational drugs, and other liver-
damaging drugs) may be related to the development of severe or prolonged adverse reactions to
mefloquine.
Implications:  We believe that people with active liver or thyroid disease should not take
mefloquine, whereas those with fully resolved neuropsychiatric illness may do so safely. Mefloquine
users should avoid alcohol, recreational drugs, hormonal contraception and co-medications known
to cause liver damage or thyroid damage. With these caveats, we believe that mefloquine may be
safely prescribed in pregnancy, and also to occupational groups who carry out safety-critical tasks.
Testing: Mefloquine's adverse effects need to be investigated through a multicentre cohort study,
with small controlled studies testing specific elements of the hypothesis.
Background
Mefloquine was developed by the US Army and intro-
duced for the treatment of malaria in the late 1970s. [1]
Mefloquine was first used for prophylaxis in 1985, and
since then approximately 14.5 million people have been
prescribed the drug for malaria prevention, versus 1.6 mil-
lion for treatment. [2]
In the first decade of mefloquine's use, the reported ad-
verse effects were mainly gastrointestinal.[3] In the late
1980s it became clear that mefloquine could cause neu-
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ropsychiatric adverse effects.[4] The first randomised con-
trolled trial of mefloquine prophylaxis in heterogeneous,
non-immune Western travellers was published in 2001
and found that one-third of all mefloquine users reported
neuropsychiatric adverse effects and 6% of all users re-
ported at least one severe adverse event (defined as requir-
ing medical advice).[5]
On the evidence from a case series published in 1992 by
the manufacturer, Hoffmann-La Roche, the World Health
Organisation (WHO) recommends that travellers with a
personal or family history of seizures or manic-depressive
illness should not take mefloquine prophylaxis.[6,7]
However the Centers for Disease Control and their Cana-
dian equivalent, CATMAT, do not recognise this as a valid
contraindication to taking mefloquine.[8]
A recent analysis of spontaneous reports held on the
Dutch national pharmacovigilance database suggested
that there is a mefloquine syndrome consisting of exces-
sive sweating accompanied by malaise, nausea, diarrhoea,
agitation, concentration problems and nightmares.[9]
The aetiology of the adverse effects associated with meflo-
quine use remains obscure. Ten cohort studies in tourists
found that women generally experienced worse side ef-
fects from mefloquine than men; [6,10–18] an eleventh
did not find this effect.[19] In randomised controlled tri-
als, children have tolerated mefloquine well. [20,21] Sur-
prisingly, one cohort study found that some older adult
travellers tolerate mefloquine better than younger adults.
[22] It has also been reported that Asian patients tolerate
mefloquine better than Caucasians and Africans. [23,24]
Despite early concerns, mefloquine appears to be safe in
pregnancy.[25]
Although the adverse effects of mefloquine are common,
and often serious and long lasting, and the drug has been
widely used for over 20 years, no real attempts have so far
been made to investigate and explain these effects. A sys-
tematic review of mefloquine prophylaxis, performed
within the Cochrane Collaboration, now tabulates 516
case reports published in 136 papers between 1976–2000,
describing adverse effects from mefloquine at prophylac-
tic and therapeutic dosages.[26]
We retrieved and critically reviewed all the original papers
listed in the Cochrane review to clarify the phenomenolo-
gy of the adverse effects associated with mefloquine, and
to look for clues to possibly safer use of the drug.
Analysis of case reports
Common features of the case reports
Of the 516 published case reports of mefloquine adverse
effects recorded in the mefloquine systematic review, 328
of the reports related to prophylactic mefloquine use, and
188 to treatment use. 324 of the 516 cases (63%) related
to tourists or business travellers.[26] One-third of the re-
ports were in languages other than English – mainly
French, German and Danish. The search strategy for find-
ing the case reports is described in the review.[26] An an-
notated bibliography of the 516 published reports can be
found at  [http://www.liv.ac.uk/evidence] .
26% of the case reports recorded three or fewer individual
patient parameters (for example, the patient's age, sex and
mefloquine dose taken), and many of these reports were
little more than a short description of an unexpected ad-
verse event, set in the context of a larger study. 52% of the
reports however contained some discussion of the causal-
ity of the symptoms attributed to the drug, and 11% pro-
posed a mechanism by which these symptoms might be
occurring.
56% of the 516 case reports we reviewed described one or
more symptoms consistent with a transient, anicteric chem-
ical hepatitis (eg, malaise, fever, anorexia, headache, ab-
dominal pain, nausea, diarrhoea, concentration
difficulties). Of the remaining reports, many were consist-
ent with a post-hepatic syndrome, although in some cases
the disorders described could have been due to conditions
such as anxiety, depression, chronic fatigue or jet lag.
15% of all the case reports described symptomatology
suggesting acutely disturbed thyroid function (eg, anorexia,
fatigue, tremor, palpitations, nervousness, increased
sweating, mood and/or sleep disturbance, memory and
concentration disorders, emotional lability, altered bowel
habit, depression).
Table 1 categorises the 516 published case reports accord-
ing to whether the clinical features were 'very likely', 'plau-
sibly' or probably 'unrelated' to liver or thyroid pathology.
We have based this classification on standard lists of the
common symptoms and signs of liver and thyroid disease.
[27,28] The direction of thyroid symptoms was mainly to-
wards hyperthyroidism, though some patients exhibited
signs of both an over- and an under-active thyroid (for ex-
ample, tachycardia alternating with bradycardia).
The table also shows the median duration of symptoms
reported by 'prophylactic' and 'treatment' mefloquine us-
ers, and the median dose taken within each category. The
median duration of adverse effects of patients who took
mefloquine as treatment appears to have been shorter
than that of those who took the drug as prophylaxis (4
days versus 16 days), even though the median dose of me-
floquine taken was higher in the treatment group. We be-
lieve that one explanation for this unexpected finding
may lie in the fact that the treatment users of mefloquineBMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/6
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were more likely to have taken the drug as monotherapy,
whereas the prophylaxis users more commonly took one
or more co-medications, as well as alcohol. We discuss the
possible significance of this later in this paper.
Mefloquine and the liver
Mefloquine is an aryl amino alcohol which accumulates
in both the liver and the lungs, and is subject to enterohe-
patic circulation. [29] It has recently been found to cause
acute hepatitis.[30]
Mefloquine does not appear to cause florid signs of liver
disease. However, transient subclinical disturbances of
liver function are a common feature of many drugs metab-
olised in the liver, and this may explain the frequent find-
ing of transaminase changes in safety studies of new
drugs; these biochemical findings are usually dismissed as
meaningless noise, but they may in fact be sensitive or
oversensitive markers of vulnerability, of low specificity.
That mefloquine induces liver enzymes is well document-
ed. Jaspers et al reported significantly raised transaminas-
es in Dutch marines who took mefloquine during 3
months in Cambodia, and who were not drinking alcohol
at the time. [31] Takeshima found that of a cohort of
healthy Japanese soldiers who took prophylactic meflo-
quine for 36 weeks without drinking alcohol, one-quarter
developed symptoms compatible with liver pathology
and four showed disturbed liver function. [32] Reisinger
et al observed the same phenomenon in a cohort of short-
stay European travellers to Africa, but it is not clear wheth-
er alcohol could have contributed to this effect.[33] One
of the travellers, who was concurrently taking a liver-dam-
aging agent, sulfadoxine,[34] showed gross morphologi-
cal changes in his liver which were attributed to his use of
prophylactic mefloquine. Liver biopsy showed intralobu-
lar cellular infiltrates consisting of macrophages and eosi-
nophils as well as sporadic eosinophilic cell necroses;
virology was negative. [33] Grieco et al described a 46-
year-old woman who drank wine daily while taking me-
floquine, and who became nervous and depressed, with
nausea, vomiting and diarrhoea. She was dehydrated and
in severe liver failure, with negative virology. Liver biopsy
showed diffuse macrovesical hepatic steatosis. [35]
'Heavy sun exposure' is noted in a case report of a 60-year-
old Frenchman who reacted acutely to his second meflo-
quine tablet; it is likely that this sun exposure would have
caused dehydration.[5] A 20-year old French traveller,
concurrently taking an oral contraceptive, had epileptic
seizures in her sixth week of mefloquine prophylaxis, di-
rectly after 'severe exertion'.[5] It seems likely that in some
mefloquine users dehydration will impose an added bur-
den on the liver, and that this could contribute to a severe
reaction to the drug. Many long-haul travellers using me-
floquine are mildly dehydrated from in-flight alcohol and
air conditioning, followed by hot and dry conditions, and
more alcohol consumption, at their holiday or business
destination.
Of the 516 case reports we reviewed, eleven cited alcohol
as possibly contributing to the adverse drug effects de-
scribed. Wittes et al reported a remarkable challenge-re-
challenge experiment where a healthy male geologist took
both his third and his fourth weekly mefloquine tablet to-
gether with half a bottle of whisky, and on both occasions
experienced acute paranoid delusions, depression and su-
icidal ideation; a fellow geologist who shared the same
whisky bottle (and who was taking no antimalaria medi-
cation) experienced no such effects.[36]
Vuurman et al, sponsored by Hoffmann-La Roche, tested
in healthy volunteers whether or not alcohol might inter-
act adversely with mefloquine.[37] They found psycho-
motor performance unimpaired, but their study design
had important limitations. Only 20 participants took me-
floquine and of these, two women dropped out due to ad-
verse events (one with nausea, vomiting and dizziness,
the other with malaise, fever and headache). The study
protocol forbade 'strenuous physical activity' and any pre-
scribed medications. Alcohol was given under strict labo-
ratory conditions 24 h after mefloquine ingestion, and
Table 1: Clinical features of published case reports of adverse effects from mefloquine, and their possible relation to liver and thyroid 
pathology
Prophylaxis case reports (N = 328) Treatment case reports (N = 188)
Number (%) of reports very likely liver related 75/328(23) 85/188(45)
Number (%) of reports plausibly but debatably liver related 102/328(31) 29/188(15)
Number (%) of reports plausibly thyroid related 51/328(16) 26/188(14)
Probably unrelated to liver or thyroid 100/328(30) 48/188(26)
Median dose (range) of mefloquine taken (mg) 750(250–8750) 1250(150–5250)
Median duration (range) of adverse effects (days) 16(1–550) 4(1–300)BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/6
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then in small and interrupted doses, such that the blood
alcohol concentration in any participant never exceeded
0.50 mg ml-1. The authors admit that their study did not
address 'the question of what might happen should (me-
floquine users) consume intoxicating amounts of alcohol.
[37] Their findings can thus not be generalised to the
broad population of tourists and business travellers.
Approximately half of the case reports listed in the Co-
chrane review note some co-medication taken along with
mefloquine.[26] Other quinoline derivatives (chiefly
chloroquine and quinine) are the commonest co-medica-
tions mentioned in the case reports. After antimalaria
drugs, an oral contraceptive (noted in 8 reports) is the
next most commonly reported co-medication, followed
by sodium valproate (7) and diazepam (4). All these
drugs can cause liver damage.[34] Diazepam is also a thy-
roid hormone antagonist, and we discuss below the pos-
sible significance of this. Meszaros et al reported a male
traveller who in addition to mefloquine took thiori-
dazine, amitriptyline and fluphenazine (all capable of
damaging the liver), and whose mefloquine-associated
neuropsychiatric symptoms persisted for over a year. [38]
Gullahorn et al reported a series of patients who experi-
enced delirium on emerging from anaesthesia, possibly
because in addition to mefloquine they had received iso-
flurane, an anaesthetic known to cause hepatocellular
necrosis. [34,39]
One report describes an acute reaction in a man who took
one mefloquine tablet each week together with two aspi-
rin tablets. One hour after taking his fifth mefloquine tab-
let he experienced acute amnesia lasting approximately
one hour.[40] Aspirin can cause hepatocellular necro-
sis,[34] and in addition can aggravate acute thyroid distur-
bance (discussed below) by competing with thyroid
hormones for sites on binding proteins.[53]
Mefloquine and the thyroid
The preclinical studies of mefloquine by the US Army in-
volved close monitoring in animal models and human
volunteers of several organ systems, but not the thyroid.
[1] The effect of mefloquine on thyroid function appears
not to have been investigated in any phase III or phase IV
study. Thyroid function has not been tested routinely in
the diagnosis or management of patients suffering from
mefloquine-related adverse effects.
Thyroid disease, or some possible interference with thy-
roid activity, is reported in only three of the 516 case re-
ports in the Cochrane review.[26] Bem et al described a
31-year old German woman with a 'thyroid condition',
who was also taking 'tranquillisers' (unspecified) and al-
cohol, and who had an acute exacerbation of her schizo-
phrenia after a single tablet of mefloquine; her symptoms
persisted for 4 weeks.[5]Conget et al reported a 30-year
old previously healthy woman who experienced abdomi-
nal pain, palpitations, instability, insomnia and a fine dis-
tal tremor in her second week of mefloquine prophylaxis.
A thyroid function screen showed a raised serum thy-
roglobulin level (54 µg/ml, normal range 18.7 to 27.1);
this returned to normal within a month of her stopping
mefloquine.[41] Bauer et al reported acute psychotic reac-
tions in a healthy US Peace Corps worker who took pro-
phylactic mefloquine concurrently with
diiodohydroxyquinoline for a presumed parasitic infec-
tion.[42]
Presentation of the hypothesis
The mefloquine syndrome
The published literature describes a mefloquine syn-
drome that presents in a variety of ways including head-
ache, gastrointestinal disturbances, nervousness, fatigue,
disorders of sleep, mood, memory and concentration, and
occasionally frank psychosis. Young western women are
particularly vulnerable to mefloquine's adverse effects.
Certain groups however (children, older adult travellers
and Asian patients) tolerate mefloquine well.
Hypothesis
The phenomenology of mefloquine's adverse effect pro-
file, together with incidental details in some of the pub-
lished case reports (references to alcohol, and to known
hepatotoxic co-medications such as the oral contraceptive
pill) suggest that for many mefloquine users adverse drug
effects may be the result of primary hepatocellular injury,
caused by the drug in association with one or more con-
current liver insults. Further, it seems that in some of these
symptomatic users of mefloquine a transient thyroid dis-
turbance may appear as well, either as an endocrine disor-
der secondary to the primary liver damage, or as an
independent pathological process.
We therefore postulate that many of the adverse effects of
mefloquine are a post-hepatic syndrome caused by prima-
ry liver damage. In some individuals we believe that
symptomatic thyroid disturbance occurs, either as an in-
dependent process, or as a secondary consequence of the
initial hepatocellular injury.
Previous liver or thyroid disease, and concurrent insults to
the liver (such as from alcohol, dehydration, an oral con-
traceptive pill, recreational drugs, and other drugs that can
damage the liver) may be related to the development of
many severe or prolonged adverse reactions to meflo-
quine. Co-medications that are thyroid hormone antago-
nists may also be risk factors.BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/6
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Relevant reports with other quinoline derivatives
Mefloquine is a synthetic quinoline; other quinolines in-
clude primaquine, amodiaquine and chloroquine.[43]
High doses of primaquine in rhesus monkeys have caused
acute fatal liver damage.[44]
Amodiaquine is still used to treat malaria, but was with-
drawn from general use for malaria prophylaxis in 1986
after it was found to cause liver damage and hepatitis,
mostly anicteric. [45,50] Some of these reports mention
co-medications known to damage liver cells (phenylbuta-
zone, oral contraceptive, alcohol). [45,46] Amodiaquine
has not been linked to disturbed thyroid function.
The possibility of a three-way interaction has already been
suggested between a quinoline derivative (chloroquine)
and the liver and the thyroid. Munera et al described a
woman with hypothyroidism, well stabilised on thyrox-
ine sodium 125 µg daily, who took prophylactic chloro-
quine and proguanil daily for 2 months for a vacation in
Africa.[51] At four weeks her thyroid stimulating hor-
mone (TSH) concentration was found to be very high
(44.8 mU/1, normal range 0.35–6.0), but it returned to
normal within a week of her stopping the drugs. Re-chal-
lenge with chloroquine and proguanil a year later again
resulted in raised levels of TSH, a lowered concentration
of free triiodothyronine (T3), and normal free thyroxine
(T4) concentration. Liver function was not tested, but the
authors speculated that 'Chloroquine... seems to have en-
hanced the induction of liver enzymes. [It] probably in-
creased the catabolism of thyroid hormones by enzymatic
induction.[51] They also suggested that chloroquine
might act centrally on the hypothalamus, through disrup-
tion of the feedback system by which thyrotropin releas-
ing hormone stimulates the pituitary to release and later
synthesise TSH.[52]
A third mechanism by which chloroquine and chemically
related drugs such as mefloquine might interfere with thy-
roid function is through structural homology to T3, result-
ing in thyroid hormone antagonism.[53] In the rat,
chloroquine injections more than halve the T3 concentra-
tion, without changing the level of free T4.[54] Chloro-
quine has been reported to inhibit T3 uptake in
mammalian cells by inhibiting receptor-mediated endo-
cytosis. [53]
Testing the hypothesis
Our hypothesis needs to be tested through a large multi-
centre cohort study of mefloquine prophylaxis in tourists
and business travellers, perhaps recruited in collaboration
with one or more airlines. Small randomised controlled
trials should test specific elements of the hypothesis, such
as the postulated link between mefloquine and thyroid
disturbance, and the presumed interaction between me-
floquine and oral contraception. National pharmacovigi-
lance databases should also be analysed systematically to
see if the spontaneous reports of mefloquine's adverse ef-
fects tend to support our hypothesis or not.
The multicentre cohort study of prophylactic mefloquine
use should be questionnaire-based, and should enquire
specifically into the major risk factors (alcohol intake dur-
ing travel, hydration status, use of hormonal contracep-
tion and recreational drugs, other potentially hepatotoxic
or thyrotoxic drugs, previous history of proven or suspect-
ed liver and/or thyroid abnormality) that we have pro-
posed. The study design should include pre- and post-
exposure testing of liver and thyroid function in at least a
sample of the cohort.
One or more case-control studies should be nested within
the cohort study. [55,56] These nested studies would al-
low for rigorous testing of the aetiological mechanisms
which we have proposed for mefloquine's adverse effects.
The studies should also resolve those prescribing issues on
which experts' opinions differ (eg, Is mefloquine safe in
pregnancy? Is it safe for long-term prophylaxis? Should
airline pilots be prescribed mefloquine? Should meflo-
quine be prescribed to people with a personal or family
history of neuropsychiatric illness? Can mefloquine be
given safely as a pre-travel loading dose, for rapid induc-
tion of chemoprophylaxis? [17,57]).
Mefloquine is a clinically important drug, commonly
used by healthy people. A much higher standard of safety
is therefore required for mefloquine prophylaxis than for
drugs given to treat serious diseases.[58,59] The study we
propose is urgently needed.
Implications of the hypothesis
What our hypothesis explains
The hypothesis explains much of the complexity of the
pattern of adverse effects of mefloquine, and also the fact
that many healthy users of the drug suffer no adverse ef-
fects at all. It also explains some aspects of mefloquine's
tolerability profile in travellers which until now have not
been understood, notably that young women experience
more adverse effects from mefloquine than men, and that
children and older adult travellers (who do not use oral
contraception, and who rarely misuse alcohol) seem to
tolerate the drug well. In addition, our hypothesis may ex-
plain the ethnic and inter individual variations in the
pharmacokinetics of this agent, which until now have not
been understood. [23,24]
It has been known for some years that mefloquine users
who take co-medications are about 1.5 times more likely
to experience an adverse drug event than those users whoBMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/6
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take no co-medications, and twice as likely to experience
severe adverse drug events.[14] The frequency of reported
adverse drug events also increases when multiple co-med-
ications are taken.[14] Our hypothesis plausibly explains
these earlier findings.
The use of marijuana and other psychoactive agents by
chloroquine users has been associated with acute psychot-
ic reactions, and it has been suggested that mefloquine us-
ers who take recreational drugs may likewise be
predisposed to neuropsychiatric problems.[60,61] We be-
lieve that this association is consistent with our hypothe-
sis, since recreational drugs can cause hepatocellular
damage and liver failure.[34]
A puzzling observation is that although the adverse effects
of mefloquine are usually reversible, in some patients
these effects can persist for months or even years after the
drug has been stopped.[61] We believe that the occasion-
ally protracted time course of the adverse effects can be
plausibly explained by supposing that in these patients
mefloquine is just one of several concurrent insults to the
liver, and that it is the continuance of the other insults
(most commonly alcohol, and certain prescription drugs)
that makes the mefloquine-induced syndrome persist.
Some published evidence supports this view.[38,62,69]
There is evidence from this study (Table 1) that the ad-
verse effects of mefloquine in those who have taken the
drug prophylactically persist longer than they do in pa-
tients who have been treated with it, even though the lat-
ter group mostly receive larger doses of the drug; this
paradox might be explained by the fact that although pro-
phylactic users usually stop mefloquine as soon as they
have experienced adverse effects, they often continue to
assault their livers in other ways, and it is this which
makes the effects persist.
Most of the reported adverse effects of mefloquine fit into
the model we propose. For example, mefloquine has been
associated with a wide variety of dermatological adverse
effects, and most of these can be linked with effects on the
liver or thyroid.[41,55] Convulsions and dizziness are
other reported effects of mefloquine which can be related
to liver or thyroid disturbance.[2,41]
Who should not take mefloquine?
We believe that people with a history of any proven or sus-
pected liver or thyroid abnormality in the previous two
years should avoid mefloquine. Travellers taking meflo-
quine should not drink alcohol, especially within 24 h of
their weekly mefloquine dose.
While taking mefloquine, travellers should be advised to
maintain good hydration with water or carbonated
drinks, especially on long plane journeys or during ardu-
ous work in hot conditions. Alcohol, tea or coffee should
not be used to maintain hydration, since they all increase
water loss.
Travellers taking mefloquine should not take a hormonal
contraceptive, nor any other drug known to injure liver
cells.[34] They should not take any drug known to antag-
onise thyroid hormone. [53] We propose that drugs that
are known to cause hepatocellular injury and also to be
thyroid hormone antagonists should be absolutely con-
traindicated in mefloquine users; such drugs include ami-
odarone, benzodiazepines, calcium channel blockers and
phenytoin.[34,53]
Because of the potential for additive toxicity, travellers
taking mefloquine should avoid concurrent use of any
other quinoline derivative (eg, amodiaquine, chloro-
quine, primaquine, quinidine, quinine, tafenoquine),
whether for additional prophylaxis or for treatment. The
administration of a different quinoline derivative at the
same time as mefloquine may increase the risk of adverse
effects.[70,72] For the same reason, mefloquine users
should avoid other quinine analogues, such as fluoroqui-
nolone antibiotics. Fluoroquinolones, such as spar-
floxacin, of loxacin and ciprofloxacin, are increasingly
prescribed in severe cases of traveller's diarrhoea, and
have been associated with severe reactions in mefloquine
users. [73]
Who should take mefloquine?
Mefloquine is a safe and exceptionally useful drug for the
mass prophylaxis and treatment of those resident popula-
tions in malaria-endemic areas which traditionally ab-
stain from alcohol and hormonal contraception. It has
been suggested that in such settings, mefloquine should
be combined with artemisinin or a derivative to protect
both drugs from resistance.[74]
On the basis of our hypothesis, we believe that children,
and also pregnant women, can safely be prescribed meflo-
quine (because neither group uses alcohol or oral contra-
ceptives).
Accompanied by explicit advice to avoid alcohol, main-
tain good hydration, and use co-medications with cau-
tion, we believe that prophylactic mefloquine could be
recommended to certain occupational subsets of travellers
who carry out safety-critical tasks and who until now have
been denied the use of this drug. These occupational
groups include airline pilots,[75] divers[76] and operators
of heavy machinery.[77]
Some authorities advise that travellers engaged in high-
risk leisure pursuits, such as mountain climbing, should
not use mefloquine. [78] We believe that this exclusion isBMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/6
Page 7 of 8
(page number not for citation purposes)
unjustified, as long as there is no recent history of liver or
thyroid disease, and provided the precautions we have
proposed above (avoidance of alcohol, maintenance of
hydration and non-use of hormonal contraception, recre-
ational drugs and certain co-medications) are adhered to.
Lobel et al consider that WHO's exclusion of people with
a personal or family history of neuropsychiatric illness
from taking mefloquine is based 'on limited evidence or
theoretical concerns', and we believe their scepticism is
justified.[79] Neuropsychiatric illness may not contrain-
dicate use of mefloquine, provided that the patient is not
currently taking anything that can cause liver damage or
thyroid disturbance.
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